Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma; Renal cancer; Skin cancer; Urogenital cancer
- Focus Therapeutic Use
- 17 Jun 2024 Planned End Date changed from 1 Sep 2024 to 1 Mar 2025.
- 17 Jun 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.
- 03 Jan 2024 Planned End Date changed from 1 Mar 2024 to 1 Sep 2024.